{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:34:17Z","timestamp":1790775257403,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cld.2025.12.005","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T10:02:04Z","timestamp":1772100124000},"page":"343-358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Algorithms for Risk Stratification in Patients with Metabolic Dysfunction-Associated Steatohepatitis"],"prefix":"10.1016","volume":"30","author":[{"given":"Angelo","family":"Armandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Bugianesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrielle","family":"Caussy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cld.2025.12.005_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.cld.2025.12.005_bib2","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort","volume":"70","author":"Simon","year":"2021","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.cld.2025.12.005_bib5","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2025.12.005_bib4","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2025.12.005_bib6","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/j.gastro.2025.02.044","article-title":"Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis","volume":"169","author":"Younossi","year":"2025","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.cld.2025.12.005_bib7","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American diabetes Association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.cld.2025.12.005_bib8","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.cld.2025.12.005_bib9","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2025.12.005_bib10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2025.12.005_bib11","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2025.12.005_bib12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2023.04.002","article-title":"Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease","volume":"79","author":"Kjaergaard","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2025.12.005_bib13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2025.12.005_bib14","article-title":"Embedding assessment of liver fibrosis into routine diabetic review in primary care","volume":"3","author":"Mansour","year":"2021","journal-title":"JHEP Rep"},{"issue":"6","key":"10.1016\/j.cld.2025.12.005_bib15","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2337\/dc24-2075","article-title":"Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study","volume":"48","author":"Caussy","year":"2025","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.cld.2025.12.005_bib16","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/HEP.0000000000000635","article-title":"Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes","volume":"79","author":"Ajmera","year":"2024","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.cld.2025.12.005_bib17","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1016\/j.cgh.2025.02.018","article-title":"Effectiveness of six international guidelines using fibrosis-4 and fibroscan for risk stratification of metabolic dysfunction-associated Steatotic Liver Disease in Type 2 Diabetes","volume":"23","author":"Vidal-Tr\u00e9can","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2025.12.005_bib18","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1136\/gutjnl-2023-330269","article-title":"Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial","volume":"72","author":"Zhang","year":"2023","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.cld.2025.12.005_bib19","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/j.cgh.2021.12.034","article-title":"Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population","volume":"20","author":"Graupera","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2025.12.005_bib20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S2468-1253(24)00274-7","article-title":"Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study","volume":"10","author":"Lindvig","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10406","key":"10.1016\/j.cld.2025.12.005_bib21","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0140-6736(23)01174-1","article-title":"Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study","volume":"402","author":"Serra-Burriel","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.cld.2025.12.005_bib22","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S2468-1253(25)00096-2","article-title":"Retina and liver fibrosis screening for patients with type 2 diabetes - authors\u2019 reply","volume":"10","author":"Lindfors","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2025.12.005_bib23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1053\/j.gastro.2024.03.017","article-title":"Metabolic dysfunction-associated fibrosis 5 (MAF-5) score predicts liver fibrosis risk and outcome in the general population with metabolic dysfunction","volume":"167","author":"van Kleef","year":"2024","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2025.12.005_bib24","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/oby.24033","article-title":"The grade of obesity affects the noninvasive diagnosis of advanced fibrosis in individuals with MASLD","volume":"32","author":"Chouik","year":"2024","journal-title":"Obesity"},{"issue":"11","key":"10.1016\/j.cld.2025.12.005_bib25","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.cgh.2023.02.024","article-title":"Validation of a clinical risk-based classification system in a large nonalcoholic fatty liver disease real-world cohort","volume":"21","author":"Sanyal","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2025.12.005_bib26","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jhep.2025.01.014","article-title":"Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease","volume":"83","author":"Yip","year":"2025","journal-title":"J Hepatol"},{"issue":"15","key":"10.1016\/j.cld.2025.12.005_bib27","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jama.2024.1447","article-title":"Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease","volume":"331","author":"Lin","year":"2024","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.cld.2025.12.005_bib28","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jhep.2019.08.019","article-title":"Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia","volume":"71","author":"Serra-Burriel","year":"2019","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2025.12.005_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2025.101789","article-title":"Economic evaluation of non-invasive test pathways for high-risk metabolic dysfunction-associated steatotic liver disease (MASLD) in the United Kingdom (UK)","volume":"30","author":"Younossi","year":"2025","journal-title":"Ann Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2025.12.005_bib30","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.cgh.2020.04.017","article-title":"Cost effectiveness of different strategies for detecting cirrhosis in patients with nonalcoholic fatty liver disease based on United States health care system","volume":"18","author":"Vilar-Gomez","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"17","key":"10.1016\/j.cld.2025.12.005_bib31","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006585","article-title":"Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients","volume":"96","author":"Phisalprapa","year":"2017","journal-title":"Medicine (Baltim)"},{"issue":"7","key":"10.1016\/j.cld.2025.12.005_bib32","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s10620-016-4044-2","article-title":"Screening for nonalcoholic steatohepatitis in individuals with type 2 diabetes: a cost-effectiveness analysis","volume":"61","author":"Corey","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.cld.2025.12.005_bib33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/liv.15730","article-title":"A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies","volume":"44","author":"Forlano","year":"2024","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.cld.2025.12.005_bib34","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16119","article-title":"Pharmaco-economic assessment of screening strategies for high-risk MASLD in primary care","volume":"45","author":"Younossi","year":"2025","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.cld.2025.12.005_bib35","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.cgh.2023.09.018","article-title":"Longitudinal outcomes associated with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of 129 studies","volume":"22","author":"Chan","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2025.12.005_bib36","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41575-025-01045-z","article-title":"Muetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment","volume":"22","author":"Byrne","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2025.12.005_bib37","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - Renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2025.12.005_bib38","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jhep.2024.05.033","article-title":"Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD","volume":"81","author":"Paternostro","year":"2024","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2025.12.005_bib39","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1097\/HEP.0000000000000616","article-title":"Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: a comparative analysis of various risk stratification criteria","volume":"79","author":"Pennisi","year":"2024","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2025.12.005_bib40","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.cgh.2021.05.002","article-title":"Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression","volume":"20","author":"Orci","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2025.12.005_bib41","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.cld.2025.12.005_bib42","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000183","article-title":"Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis","volume":"7","author":"Behari","year":"2023","journal-title":"Hepatol Commun"},{"issue":"12","key":"10.1016\/j.cld.2025.12.005_bib43","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.cgh.2024.07.003","article-title":"Expert panel recommendations: practical clinical applications for initiating and monitoring resmetirom in patients with MASH\/NASH and moderate to noncirrhotic advanced fibrosis","volume":"22","author":"Noureddin","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2025.12.005_bib44","article-title":"Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions","volume":"4","author":"Anstee","year":"2022","journal-title":"JHEP Rep"},{"issue":"3","key":"10.1016\/j.cld.2025.12.005_bib45","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/hep.30864","article-title":"Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts","volume":"71","author":"Aberg","year":"2020","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2025.12.005_bib46","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jhep.2024.06.036","article-title":"Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease","volume":"81","author":"Marti-Aguado","year":"2024","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2025.12.005_bib47","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S2468-1253(23)00206-6","article-title":"MetALD: new opportunities to understand the role of alcohol in steatotic liver disease","volume":"8","author":"Israelsen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2025.12.005_bib48","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1136\/gutjnl-2024-333074","article-title":"Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease","volume":"73","author":"Zhou","year":"2024","journal-title":"Gut"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125001072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125001072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:57:55Z","timestamp":1778878675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326125001072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1089326125001072"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2025.12.005","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Algorithms for Risk Stratification in Patients with Metabolic Dysfunction-Associated Steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2025.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}